Lexeo Therapeutics Common Stock Statistics
Share Statistics
Lexeo Therapeutics Common Stock has 33.07M shares outstanding. The number of shares has increased by 0.36% in one year.
| Shares Outstanding | 33.07M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 23.81M |
| Failed to Deliver (FTD) Shares | 200 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 2.19M, so 6.63% of the outstanding shares have been sold short.
| Short Interest | 2.19M |
| Short % of Shares Out | 6.63% |
| Short % of Float | 9.21% |
| Short Ratio (days to cover) | 6.55 |
Valuation Ratios
The PE ratio is -5.39 and the forward PE ratio is -2.78.
| PE Ratio | -5.39 |
| Forward PE | -2.78 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 3.15 |
| P/FCF Ratio | -5.99 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lexeo Therapeutics Inc. Common Stock.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.21, with a Debt / Equity ratio of 0.1.
| Current Ratio | 7.21 |
| Quick Ratio | 7.21 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 9.3 |
| Cash Flow / Debt | -5.11 |
| Interest Coverage | -334.21 |
Financial Efficiency
Return on equity (ROE) is -0.58% and return on capital (ROIC) is -54.73%.
| Return on Equity (ROE) | -0.58% |
| Return on Assets (ROA) | -0.47% |
| Return on Capital (ROIC) | -54.73% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -962.23K |
| Employee Count | 69 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -64.02% in the last 52 weeks. The beta is 0, so Lexeo Therapeutics Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -64.02% |
| 50-Day Moving Average | 7.13 |
| 200-Day Moving Average | 11.26 |
| Relative Strength Index (RSI) | 37.02 |
| Average Volume (20 Days) | 381.78K |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.84M |
| Operating Income | -68.51M |
| Net Income | -66.39M |
| EBITDA | -66.67M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.49 |
Balance Sheet
The company has 121.47M in cash and 11.64M in debt, giving a net cash position of 109.83M.
| Cash & Cash Equivalents | 121.47M |
| Total Debt | 11.64M |
| Net Cash | 109.83M |
| Retained Earnings | -181.84M |
| Total Assets | 173.87M |
| Working Capital | 132.64M |
Cash Flow
In the last 12 months, operating cash flow was -59.50M and capital expenditures -165.00K, giving a free cash flow of -59.66M.
| Operating Cash Flow | -59.50M |
| Capital Expenditures | -165.00K |
| Free Cash Flow | -59.66M |
| FCF Per Share | -2.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LXEO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -42.86% |
| FCF Yield | -31.06% |
Analyst Forecast
The average price target for LXEO is $24.5, which is 321.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $24.5 |
| Price Target Difference | 321.7% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.35 |
| Piotroski F-Score | 2 |